232 related articles for article (PubMed ID: 22432610)
1. Engineering antibodies for cancer therapy.
Boder ET; Jiang W
Annu Rev Chem Biomol Eng; 2011; 2():53-75. PubMed ID: 22432610
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
3. Recombinant antibodies for the diagnosis and treatment of cancer.
Krauss J
Mol Biotechnol; 2003 Sep; 25(1):1-17. PubMed ID: 13679630
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic antibodies and antibody fusion proteins.
Rohrbach P; Broders O; Toleikis L; Dübel S
Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
[No Abstract] [Full Text] [Related]
5. Antibody engineering.
Maynard J; Georgiou G
Annu Rev Biomed Eng; 2000; 2():339-76. PubMed ID: 11701516
[TBL] [Abstract][Full Text] [Related]
6. Antibody Engineering--IBC's 17th annual international conference. Antibody engineering and immunotherapeutics for the 21st century.
Bradbury A
IDrugs; 2007 Mar; 10(3):169-72. PubMed ID: 17351868
[No Abstract] [Full Text] [Related]
7. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
8. Generation of antibody molecules through antibody engineering.
Kipriyanov SM
Methods Mol Biol; 2003; 207():3-25. PubMed ID: 12412465
[No Abstract] [Full Text] [Related]
9. Engineering antibody therapeutics.
Chiu ML; Gilliland GL
Curr Opin Struct Biol; 2016 Jun; 38():163-73. PubMed ID: 27525816
[TBL] [Abstract][Full Text] [Related]
10. IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.
Arnett SO; Teillaud JL; Wurch T; Reichert JM; Dunlop C; Huber M
MAbs; 2011; 3(2):133-52. PubMed ID: 21304271
[TBL] [Abstract][Full Text] [Related]
11. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
12. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
Niwa R; Satoh M
J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical determinants of antibody-protein interactions.
Karadag M; Arslan M; Kaleli NE; Kalyoncu S
Adv Protein Chem Struct Biol; 2020; 121():85-114. PubMed ID: 32312427
[TBL] [Abstract][Full Text] [Related]
14. Discovery of internalizing antibodies to tumor antigens from phage libraries.
Zhou Y; Marks JD
Methods Enzymol; 2012; 502():43-66. PubMed ID: 22208981
[TBL] [Abstract][Full Text] [Related]
15. Recombinant antibodies for cancer diagnosis and therapy.
Hudson PJ; Souriau C
Expert Opin Biol Ther; 2001 Sep; 1(5):845-55. PubMed ID: 11728219
[TBL] [Abstract][Full Text] [Related]
16. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
Igawa T
Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.
Hendriks D; Choi G; de Bruyn M; Wiersma VR; Bremer E
Int Rev Cell Mol Biol; 2017; 331():289-383. PubMed ID: 28325214
[TBL] [Abstract][Full Text] [Related]
18. Engineering at the limits of antibody space.
Huston JS
Protein Eng Des Sel; 2013 Oct; 26(10):559-60. PubMed ID: 24077692
[No Abstract] [Full Text] [Related]
19. Recombinant bispecific antibodies for cancer therapy.
Kontermann RE
Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
[TBL] [Abstract][Full Text] [Related]
20. Replacing antibodies: engineering new binding proteins.
Banta S; Dooley K; Shur O
Annu Rev Biomed Eng; 2013; 15():93-113. PubMed ID: 23642248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
